about
The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNAIdentification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands.Signatures of protective memory immune responses during hepatitis C virus reinfection.Increased numbers of CD5+CD19+CD1dhighIL-10+ Bregs, CD4+Foxp3+ Tregs, CD4+CXCR5+Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients.Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.Will there be a vaccine to prevent HCV infection?Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations.Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8⁺ T cells in early viral evolution.Activation and evasion of antiviral innate immunity by hepatitis C virus.Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection.Fueling fibrosis in chronic hepatitis C.Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis.Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviralIL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based testImmunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1).KLRG1 negatively regulates natural killer cell functions through the Akt pathway in individuals with chronic hepatitis C virus infection.Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity.Will there be a vaccine to protect against the hepatitis C virus?HLA-B*27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope.Progress towards a hepatitis C virus vaccine.Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzeeHost genetics in immune-mediated hepatitis C virus clearance.Failure of innate and adaptive immune responses in controlling hepatitis C virus infection.Hepatitis C virus evasion mechanisms from neutralizing antibodiesCurrent progress in development of hepatitis C virus vaccines.Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies.The proportion of different interleukin-17-producing T-cell subsets is associated with liver fibrosis in chronic hepatitis C.HCV-infected hepatocytes drive CD4+ CD25+ Foxp3+ regulatory T-cell development through the Tim-3/Gal-9 pathway.T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee.Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection.A siege of hepatitis: immune boost for viral hepatitis.Immunodominance of HLA-A2-restricted hepatitis C virus-specific CD8+ T cell responses is linked to naive-precursor frequency.Roles of hepatic stellate cells in liver inflammation: a new perspective.The relationship between human leukocyte antigen-DP/DQ gene polymorphisms and the outcomes of HCV infection in a Chinese population.Interaction of Hepatitis C Viral Proteins with Cellular Oncoproteins in the Induction of Liver Cancer
P2860
Q26800446-969B5C2D-6739-4A13-BBBC-DD2DA464B852Q34123618-4E2D3F31-44F3-46DB-8DBC-15D7C0A0770AQ34219029-B6C1E997-EFBA-40EF-A462-482C812077B3Q34235321-B372F03F-3290-4F18-B806-CDAE96DD2132Q34449537-485F699A-598E-44BC-9684-535E4EA61B45Q34781537-5CD50404-1314-4B91-B4BF-F955B02E0F9AQ35446259-C7AD09FC-37F6-42FB-B1BF-89F4190D255EQ35531150-670A01A9-7B2D-4F0A-9E16-4A1E121B7CFAQ35606341-063DD52A-9B0C-4965-8347-F298069F20ADQ35787699-0416B5C5-CCF5-43F7-B4DD-46D74C6789C4Q36131706-AE902B0B-B9A1-431B-8DCF-CC7F46EA9F86Q36221650-2AF03337-4A29-46BE-A074-48B962365834Q36221675-294E95AC-0E27-4FB6-8361-3C31855A8912Q36823319-1F38D71D-8DC0-4A8F-896D-567E058C82C2Q36836988-1608220B-C225-4B3C-A674-AF7581C5537BQ37173264-51CBE8EE-09A0-4B6C-B200-9BB75C6AFC53Q37252732-A6374A94-FA2D-4441-8C9B-9E4145721FAAQ37374059-FEB6C689-5347-47BD-AC69-66D17498BBDCQ37389655-D70CE8FE-0690-4006-A210-FE62269971E3Q37402195-E5461E5F-40CA-4AB7-8A59-3786C1713F25Q37584338-093139BB-1391-4DDD-AB24-38ADC2D6DA3EQ37713524-3732FD79-ECF5-499D-8F6C-14973501516EQ37862746-408E0B0E-3B9F-49A1-9EE1-E43630003EB0Q37964746-E7636432-4C77-400F-A4F6-CD150171660DQ37967737-8EA53252-4036-4B06-8F5B-5E08043AD1F6Q38120201-B5A75F1E-1EAB-41B1-A407-18F7DF4C0C04Q38265395-806B59EE-C670-4D9C-8E48-CC6246DE9B5FQ40351950-8207E83A-2018-4BEC-A31F-06BDA7AC9C99Q41894013-CF1BCD57-761C-40F7-BCF4-E300FEB82383Q42061089-B8C040FB-B748-4AC8-985B-A2FAAB8CF77EQ42071282-632062AF-6F3B-4F01-905D-65E8BBA273ABQ42140400-DC57677F-23A7-4672-A37A-3CF5EA8DE739Q42779714-3A7EE7CE-DF12-47D0-991A-0638650AB0D2Q47094246-D43EB33D-D791-40CF-82AF-230D1A5CFBB2Q47103710-BB2178F0-8159-4706-ABDC-C45887261658Q59047334-F609E62B-D097-4CEE-81B9-EFF7B817BFF8
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adaptive immunity to the hepatitis C virus.
@en
Adaptive immunity to the hepatitis C virus.
@nl
type
label
Adaptive immunity to the hepatitis C virus.
@en
Adaptive immunity to the hepatitis C virus.
@nl
prefLabel
Adaptive immunity to the hepatitis C virus.
@en
Adaptive immunity to the hepatitis C virus.
@nl
P2860
P1476
Adaptive immunity to the hepatitis C virus.
@en
P2093
Christopher M Walker
P2860
P356
10.1016/B978-0-12-385032-4.00002-1
P577
2010-01-01T00:00:00Z